aKRAS: Lead candidate in colorectal cancer
Oblique has developed aKRAS with the Abiprot™ platform, antagonistic antibodies with a single amino acid selectivity against mutated KRAS.
About KRAS-mutated colorectal cancer
Sometimes referred to as bowel and colon cancer, colorectal cancer is a malignancy of the intestine. According to recent reports from WHO, around 1.8 million people are estimated to fall ill to the disease under 2018, making it the world’s third most prevalent cancer form. Although significant progress has been made in colorectal cancer treatment during the last decade with the approval of multiple new agents, such as VEGF and EFGR targeted therapies, the prognosis for patients with colorectal cancer remains poor. Nearly 900 000 people are estimated to succumb to the disease in 2018 alone. Resistance to therapy remains a major obstacle in effective treatment and many patients do not receive any clinical benefit from standard of care treatment. A meditator of resistance to anti-EGFR therapy is a mutation in the KRAS-gene, a genetic driver for malignant transformation, found in approximately 30-50% of cases.
In 2018, it is estimated that 540 000-900 000 individuals are to be afflicted with KRAS-mutated colorectal cancers and, therefore, likely to see little to no benefit from the standard of care EFGR targeted treatments. The KRAS-mutated market within the seven major markets (Germany, France, Italy, Japan, Spain, UK and the U.S.) is roughly estimated to range between 1.65 to 2.75 billion USD annually and, is expected to grow.
1. Markman, M. W. M. L. ”Colorectal cancer and KRAS/SBRAF.” Medscape (2014). Updated 2018. Accessed 24 September 2018. 2. Wilson PM, Labonte MJ, Lenz HJ. Molecular markers in the treatment of metastatic colorectal cancer. Cancer J. 2010 May-Jun. 16(3):262-72. 3. Porru, Manuela, et al. ”Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.” Journal of Experimental & Clinical Cancer Research 37.1 (2018): 57. 4. Datamonitor Healthcare Colorectal Cancer Patient based Forecast Report 2016-2015